D9Z.F · Clínica Baviera, S.A

-

Please sign in to comment on D9Z.F

1 Comment

Admin

4 years, 1 month ago

Clínica Baviera, S.A is currently in a long term uptrend where the price is trading 17.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.

Clínica Baviera, S.A's total revenue sank by 6.4% to $33M since the same quarter in the previous year.

Its net income has increased by 12.3% to $5M since the same quarter in the previous year.

Finally, its free cash flow grew by 150.2% to $11M since the same quarter in the previous year.

Based on the above factors, Clínica Baviera, S.A gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	ES0119037010
Sector	Healthcare
Industry	Diagnostics & Research

Market Cap	584M
PE Ratio	14.78
Target Price	None
Dividend Yield	4.3%
Beta	0.68

ABOUT

Clínica Baviera, S.A

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmology, tear ducts, oculoplasty, lasik, lasek, and intraocular lenses treatments. The company was formerly known as Clínica Oftalmológica Baviera, S.L. and changed its name to Clínica Baviera, S.A. in 2000. Clínica Baviera, S.A. was incorporated in 1992 and is headquartered in Madrid, Spain. Clínica Baviera, S.A. is a subsidiary of Aier Eye International (Europe), S.L.U.

D9Z.F · Clínica Baviera, S.A

-

Clínica Baviera, S.A

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Clínica Baviera, S.A using a moving average strategy